CRP and metabolic syndrome: S-TMAO (microbial-derived choline metabolite) levels were dose-dependent associated with CVD outcomes and other indicators such as serum cholesterol, glycaemic indices (HbA1c, fasting plasma glucose), inflammation biomarkers (IL-6, CRP), overall cardiovascular risk, and metabolic syndrome.